[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ureteral-stents\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ureteral-stents":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100641796","phase-3-stent-x-a-randomized-trial-to-assess-stent-free-radical-cystectomy-100641796",false,"NCT07655284","STENT X: a Randomized Trial to Assess Stent-free Radical Cystectomy","STENT X Non-stent Genito-urinary Tract Reconstruction After Radical Cystectomy for Bladder Cancer - a Prospective, Randomized, Controlled and Multi Institutional Trial","Inclusion Criteria:\n\n* Adults (\\> 18 years old)\n* Muscle invasive bladder cancer or non-muscle invasive bladder cancer with indication of Radical Cystectomy\n* No concomitant surgeries like nephrectomies, colectomies or removal of other organs affected by the tumor (Except standard lymph node dissections as well as in men the prostate and seminal vesicles and in women the uterus, fallopian tubes, ovaries and vagina, that are considered part of the oncological radical cystectomy.)\n* Patients who have the capacity to understand the study procedures and provide written informed consent\n\nExclusion Criteria:\n\n* Simultaneous surgical procedures (except those specified in the inclusion criteria that are considered part of a routine radical cystectomy)\n* History of prior urinary diversion\n* Patients who decline to participate, lack understanding of the study's purpose, or are unable to provide informed consent\n* Cystectomy for other reasons than Bladder cancer\n* Previous radiation therapy in the pelvis for any reason\n* Extremely debilitated patients, malnourished individuals, or those undergoing palliative or hygienic cystectomy","ALL","18 Years",{"count":19,"type":20},190,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","Radical Cystectomy (RC) remains the gold standard for localized muscle-invasive bladder cancer (MIBC); however, use of ureteral stents at time of surgery remains controversial without level 1 evidence to comment on risks or benefits of their use. RC complications commonly include urinary tract infections (UTIs), pyelonephritis, ureteroileal leakage and stenosis, and can occur with either ileal conduit or orthotopic neobladder diversions. Traditionally, ureteral stents are thought to support anastomotic healing and reduce the risk of anastomotic leakage and strictures; however, emerging evidence from retrospective studies suggests that stent use may paradoxically increase rates of postoperative morbidity. This randomized, multicenter and prospective study aims to compare 30-day postoperative complication rates between stented and non-stented urinary diversions in patients undergoing RC for MIBC, in both ileal conduit or neobladder with either robotic or open approaches.",[26,27],"Bladder Cancer Requiring Cystectomy","Ureteral Stents",[29,30,31],"bladder cancer","cystectomy","ureteral stents","NOT_YET_RECRUITING","2026-06-17",{"date":35,"type":36},"2026-06-22","ACTUAL",{"date":38,"type":20},"2026-09-01",{"date":40,"type":20},"2029-08-31",{"name":42,"class":43},"Brigham and Women's Hospital","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":56,"conditions":57,"keywords":62,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":5},"100642199","phase-3-assessing-suzetrigine-for-pain-reduction-following-ureteroscopic-surgery-100642199","NCT07654296","Assessing Suzetrigine for Pain Reduction Following Ureteroscopic Surgery","Multimodal Analgesia Pathway Assessing Role of Suzetrigine for the Reduction of Opioid Use Following Ureteroscopic Surgery","Inclusion Criteria:\n\n* Patients undergoing ureteroscopy between ages 21 to 80 at BWFH (Brigham \\& Women's Faulkner Hospital) by one of the department's high volume endoscopic surgeons. Patient who are or not pre-stented prior to surgery will be included (these will be assessed via stratification within a secondary analysis).\n* Patients able to consent for their own medical care (i.e. consent able to be obtained directly from patient and does not require a healthcare proxy or guardian)\n\nExclusion Criteria:\n\n* Regular opioid use prior to surgery or significant substance abuse concerns.\n* Inability of patient to provide their own consent (i.e. lack capacity).","21 Years","80 Years",{"count":54,"type":20},100,[23],"Urologic surgery has advanced with new technologies to allow less invasive management of common afflictions such as kidney stones, these procedures are notoriously painful as the ureter must be dilated to accommodate any instruments, and a ureteral stent is often left following surgery to allow for adequate healing. Unfortunately, stents are poorly tolerated by a significant number of patients, with up to 100% complaining of bothersome pain and 10% of patients with unplanned healthcare visits. Further complicating kidney stone management is the frequency of concurrent chronic kidney disease (CKD) or acute kidney injury (AKI) that prohibits many patients from taking NSAIDs which limits pain management options. There is now a push to treat these patients with multimodal analgesia to provide better care and reduce opioid use. Suzetrigine is a new a first-in-class selective inhibitor of the NaV1.8 sodium channel that functions as a non-opioid analgesic developed to treat acute pain and neuropathic pain. This study assesses the addition of suzetrigine to standard-of-care multimodal analgesia. We hypothesize a demonstrated decrease in opioid use, decrease Emergency Room visits within 30 days, decrease the number of unplanned care encounters.",[58,59,60,27,61],"Opioid Consumption, Postoperative","Multimodal Analgesia","Ureteroscopy","Ureteral Stent-Related Symptoms",[59,63,64,31],"Postoperative Opioid Consumption","ureteroscopy","2026-06-12",{"date":33,"type":36},{"date":68,"type":20},"2026-08-01",{"date":70,"type":20},"2027-03-31",{"name":42,"class":43}]